Scientists Appeal Decision In Eli Lilly Patent Suit

Law360, New York (May 10, 2006, 12:00 AM EDT) -- Doctors that allege they co-discovered a gene used in Eli Lilly’s high-earning drug Xigris, appealed last Friday a decision by a judge in support of the giant pharmaceutical company.

Gerald Crabtree and his former research colleague Jorge Plutzky contend that they cloned a Protein C gene, and that Lilly that did not include their names when it filed a patent for the gene in order to avoid paying royalties.

Xigris, which is used to combat the blood infection sepsis, earned $215 million for Lilly last year....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.